US Stock MarketDetailed Quotes
KROS Keros Therapeutics
- 52.510
- -1.170-2.18%
Close Sep 6 16:00 ET
- 52.510
- 0.0000.00%
Post 20:02 ET
1.97BMarket Cap-10235P/E (TTM)
54.820High51.810Low402.86KVolume53.830Open53.680Pre Close21.32MTurnover1.24%Turnover RatioLossP/E (Static)37.52MShares73.00052wk High4.68P/B1.70BFloat Cap27.02052wk Low--Dividend TTM32.39MShs Float88.800Historical High--Div YieldTTM5.61%Amplitude19.100Historical Low52.913Avg Price1Lot Size
Keros Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -29.09%-39.8M | -30.16%-44.56M | -77.71%-124.51M | -18.73%-25.46M | -38.13%-33.98M | -36.49%-30.83M | -2,299.09%-34.24M | -12.73%-70.06M | -9.60%-21.44M | -70.36%-24.6M |
| Net income from continuing operations | -20.67%-45.26M | -20.42%-43.11M | -46.15%-152.99M | -35.42%-40.24M | -67.77%-39.44M | -37.55%-37.51M | -48.04%-35.8M | -78.20%-104.68M | -328.21%-29.72M | -15.82%-23.51M |
| Operating gains losses | ---- | ---- | -66.67%4K | --0 | --0 | --0 | --4K | -73.91%12K | -96.15%1K | ---- |
| Depreciation and amortization | 60.21%306K | 65.87%277K | 20.92%815K | 94.49%247K | 66.67%210K | -37.99%191K | 47.79%167K | 78.31%674K | 22.12%127K | 22.33%126K |
| Other non cash items | -2.26%346K | -35.06%339K | 64.93%1.55M | 4.36%335K | 61.61%341K | 71.84%354K | 157.14%522K | 80.96%941K | -64.61%321K | 135.82%211K |
| Change In working capital | -336.04%-3.98M | -110.60%-10.13M | -118.52%-2.65M | 123.31%6.88M | 38.60%-3.8M | -44.46%-913K | -126.65%-4.81M | 189.04%14.31M | 118.16%3.08M | -290.15%-6.2M |
| -Change in receivables | --222K | ---83K | -100.79%-143K | ---143K | --0 | --0 | --0 | 200.00%18M | --0 | --0 |
| -Change in prepaid assets | -327.54%-6.37M | -9.92%-4.48M | -179.55%-9.28M | 299.63%539K | -1,584.32%-4.26M | 63.70%-1.49M | -633.25%-4.07M | -114.53%-3.32M | -120.35%-270K | 155.09%287K |
| -Change in payables and accrued expense | 316.75%2.51M | -713.89%-5.33M | 39.82%6.87M | 40.61%6.83M | 102.48%92K | -85.21%603K | -113.36%-655K | 18.78%4.91M | 569.15%4.86M | -220.16%-3.71M |
| -Change in other current assets | ---- | ---- | 69.63%-478K | ---478K | --0 | ---- | ---- | ---1.57M | --0 | ---- |
| -Change in other current liabilities | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
| -Change in other working capital | -1,100.00%-324K | -192.68%-240K | 110.35%384K | 108.55%129K | 130.46%364K | 95.54%-27K | 79.60%-82K | -521.61%-3.71M | -51.71%-1.51M | ---1.2M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -29.09%-39.8M | -30.16%-44.56M | -77.71%-124.51M | -18.73%-25.46M | -38.13%-33.98M | -36.49%-30.83M | -2,299.09%-34.24M | -12.73%-70.06M | -9.60%-21.44M | -70.36%-24.6M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0.32%-310K | 10.92%-946K | -98.55%-2.46M | -54.13%-541K | -212.50%-550K | 45.15%-311K | -622.45%-1.06M | -21.19%-1.24M | -120.75%-351K | -21.38%-176K |
| Net PPE purchase and sale | 0.32%-310K | 10.92%-946K | -98.55%-2.46M | -54.13%-541K | -212.50%-550K | 45.15%-311K | -622.45%-1.06M | -21.19%-1.24M | -120.75%-351K | -21.38%-176K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 0.32%-310K | 10.92%-946K | -98.55%-2.46M | -54.13%-541K | -212.50%-550K | 45.15%-311K | -622.45%-1.06M | -21.19%-1.24M | -120.75%-351K | -21.38%-176K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 102.93%3.53M | 45.62%156.8M | 48.75%178.96M | 12.76%69.25M | -99.42%284K | -82.93%1.74M | 91,152.54%107.68M | 321.40%120.31M | 116.13%61.42M | 138,708.57%48.58M |
| Net common stock issuance | --629K | 41.03%151.34M | 47.04%175.83M | 11.59%68.52M | --0 | --0 | --107.31M | 324.47%119.58M | 117.96%61.4M | --48.49M |
| Proceeds from stock option exercised by employees | 70.52%2.97M | 1,446.22%5.72M | 294.25%3.23M | 688.24%804K | 223.96%311K | 246.61%1.74M | 213.56%370K | 115.83%818K | -58.37%102K | 174.29%96K |
| Net other financing activities | ---65K | ---259K | -8.05%-94K | ---67K | ---- | ---- | ---- | ---87K | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 102.93%3.53M | 45.62%156.8M | 48.75%178.96M | 12.76%69.25M | -99.42%284K | -82.93%1.74M | 91,152.54%107.68M | 321.40%120.31M | 116.13%61.42M | 138,708.57%48.58M |
| Net cash flow | ||||||||||
| Beginning cash position | 25.77%443.66M | 18.54%332.36M | 21.18%280.38M | 20.08%289.11M | 49.05%323.35M | 53.43%352.76M | 21.18%280.38M | -13.02%231.37M | 8.12%240.75M | -8.55%216.95M |
| Current changes in cash | -24.41%-36.58M | 53.76%111.3M | 6.08%51.98M | 9.17%43.25M | -243.87%-34.25M | -126.79%-29.4M | 5,071.22%72.38M | 241.55%49.01M | 355.84%39.62M | 263.60%23.81M |
| End cash Position | 25.89%407.08M | 25.77%443.66M | 18.54%332.36M | 18.54%332.36M | 20.08%289.11M | 49.05%323.35M | 53.43%352.76M | 21.18%280.38M | 21.18%280.38M | 8.12%240.75M |
| Free cash flow | -28.80%-40.11M | -28.92%-45.51M | -78.07%-126.97M | -19.30%-26M | -39.37%-34.53M | -34.49%-31.14M | -2,142.50%-35.3M | -12.87%-71.3M | -10.49%-21.79M | -69.88%-24.78M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg